Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand

Nasamon Wanlapakorn; Nungruthai Suntronwong; Sitthichai Kanokudom; Suvichada Assawakosri; Pornjarim Nilyanimit; Ritthideach Yorsaeng; Jira Chansaenroj; Yong Poovorawan

doi:10.1080/20477724.2022.2108646

Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand

Pathog Glob Health. 2022 Oct;116(7):395-397. doi: 10.1080/20477724.2022.2108646. Epub 2022 Aug 3.

Authors

Nasamon Wanlapakorn¹, Nungruthai Suntronwong¹, Sitthichai Kanokudom¹, Suvichada Assawakosri¹, Pornjarim Nilyanimit¹, Ritthideach Yorsaeng¹, Jira Chansaenroj¹, Yong Poovorawan^{1

2}

Affiliations

¹ Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
² FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, Thailand.

No abstract available

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
Thailand / epidemiology

Substances

Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine

Grants and funding

This work was supported by the National Research Council of Thailand, the Health Systems Research Institute, the Center of Excellence in Clinical Virology of Chulalongkorn University, King Chulalongkorn Memorial Hospital, MK Restaurant Group, and the Second Century Fund Fellowship of Chulalongkorn University.